Yogesh Chutake

I am a translational medicine leader with 12+ years of expertise in oncology and neurodegenerative diseases, bridging preclinical discovery to early-phase clinical trials. Known for strategic leadership in disease biology, biomarker strategy, and assay development, I excel at driving innovative drug discovery programs targeting solid tumors, myeloid malignancies, and rare genetic diseases. As Associate Director of Translational Medicine at Kymera Therapeutics, I spearheaded the KT-253 program—a novel MDM2 degrader in Phase 1 trials—by developing biomarker strategies for proof of mechanism and biology, leading cross-functional collaborations, and managing clinical sample analysis through central labs and CRO partnerships. With a proven track record in strategic project leadership, I have successfully advanced early-stage programs to regulatory filings and clinical trials while building high-impact collaborations with key opinion leaders, academic institutions, and industry stakeholders. As a dedicated mentor, I have recruited and developed talented teams, empowering them to deliver transformative results. I thrive at the intersection of science and strategy, leveraging my expertise to unlock the full potential of translational medicine and deliver therapies that make a meaningful difference in patients' lives.